Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination.
Pejoski D., de Rham C., Martinez-Murillo P., Santoro F., Auderset F., Medaglini D., Pozzi G., Vono M., Lambert P-H., Huttner A., Haks MC., Ottenhoff THM., Villard J., Siegrist C-A., VEBCON Consortium None., VSV-EBOVAC Consortium None., VSV-EBOPLUS Consortium None.
The rVSV-ZEBOV Ebolavirus vaccine confers protection within days after immunization, suggesting the contribution of innate immune responses. We report modulation of rVSV-ZEBOV vaccinee blood CD56<sup>+</sup> NK cell numbers, NKG2D or NKp30 surface receptor expression, Killer Immunoglobulin-like Receptor (KIR)<sup>+</sup> cell percentages and NK-cell-related genes on day 1 post immunization. Inverse correlations existed between the concentration of several plasma cytokines and inhibitory KIR<sup>+</sup> CD56<sup>dim</sup> or cytokine-responsive CD56<sup>bright</sup> NK cells. Thus, NK cells may contribute to the early protective efficacy of rVSV-ZEBOV in humans.